BACKGROUND: The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear. AIM OF STUDY: To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study. METHODS: A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma. RESULTS: Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of > or = 20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2-23.5) compared to 7.6+ months (range 4.0-14.7) in those without such a change (p = 0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0-41.4) vs 6.2 months (range 3.1-9.4; p = 0.0075). CONCLUSIONS: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice.
BACKGROUND: The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear. AIM OF STUDY: To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study. METHODS: A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma. RESULTS:Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of > or = 20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2-23.5) compared to 7.6+ months (range 4.0-14.7) in those without such a change (p = 0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0-41.4) vs 6.2 months (range 3.1-9.4; p = 0.0075). CONCLUSIONS: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice.
Authors: Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl Journal: Int J Gastrointest Cancer Date: 2002
Authors: R A Abrams; L B Grochow; A Chakravarthy; T A Sohn; M L Zahurak; T L Haulk; S Ord; R H Hruban; K D Lillemoe; H A Pitt; J L Cameron; C J Yeo Journal: Int J Radiat Oncol Biol Phys Date: 1999-07-15 Impact factor: 7.038
Authors: Y Shibamoto; T Manabe; G Ohshio; K Sasai; Y Nishimura; M Imamura; M Takahashi; M Abe Journal: Int J Radiat Oncol Biol Phys Date: 1996-01-01 Impact factor: 7.038
Authors: Oliver Micke; Frank Bruns; Rene Kurowski; Eckehard Horst; Alexander F deVries; John W Hausler; Normann Willich; Ulrich Schäfer Journal: Int J Radiat Oncol Biol Phys Date: 2003-09-01 Impact factor: 7.038
Authors: C Ziske; C Schlie; M Gorschlüter; A Glasmacher; U Mey; J Strehl; T Sauerbruch; I G H Schmidt-Wolf Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal Journal: HPB (Oxford) Date: 2016-07-14 Impact factor: 3.647
Authors: J L Humphris; D K Chang; A L Johns; C J Scarlett; M Pajic; M D Jones; E K Colvin; A Nagrial; V T Chin; L A Chantrill; J S Samra; A J Gill; J G Kench; N D Merrett; A Das; E A Musgrove; R L Sutherland; A V Biankin Journal: Ann Oncol Date: 2012-01-11 Impact factor: 32.976
Authors: Christian Pfrepper; Maren Knödler; Ruth Maria Schorling; Daniel Seehofer; Sirak Petros; Florian Lordick Journal: J Cancer Res Clin Oncol Date: 2021-09-09 Impact factor: 4.322
Authors: Felix Hahn; Lukas Müller; Florian Jungmann; Aline Mähringer-Kunz; Yasemin Tanyildizi; Christoph Düber; Peter R Galle; Arndt Weinmann; Roman Kloeckner Journal: J Cancer Res Clin Oncol Date: 2020-03-30 Impact factor: 4.553
Authors: Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa Journal: Cancers (Basel) Date: 2022-03-15 Impact factor: 6.639